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Atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence of at least 3% in the adult 
population of Sweden.1 AF is a major risk factor for stroke, 
giving patients with this condition a 5-fold increased risk of 
suffering a stroke.2 Both the prevalence of AF and the related 
stroke risk increase markedly in the elderly.2 Treatment 
with an oral anticoagulant (OAC) reduces the risk for stroke 
effectively.3–5 Vitamin K antagonists, such as warfarin have 
been the mainstay for stroke prevention in AF patients for 
several decades.6 However, many patients, especially the 
elderly and frail, have received less efficient but not safer 
acetylsalicylic acid (ASA) or no antithrombotic treatment 
at all.7 Previous studies in Sweden indicated that the largest 
preventable stroke burden was among elderly patients not 
receiving warfarin treatment.8,9
Four pivotal trials have shown the efficacy and safety of 
the non–vitamin K antagonist OACs (NOACs) dabigatran, 
rivaroxaban, apixaban, and edoxaban compared with warfa-
rin.10–13 Numerous observational studies have corroborated 
their safety and effectiveness in clinical practice.14,15 The 
© 2018 American Heart Association, Inc.
Background and Purpose—The purpose of this study was to investigate the impact of improved antithrombotic treatment 
in atrial fibrillation after the introduction of non–vitamin K antagonist oral anticoagulants on the incidence of stroke and 
bleeding in a real-life total population, including both primary and secondary care.
Methods—All resident and alive patients with a recorded diagnosis for atrial fibrillation during the preceding 5 years in 
the Stockholm County Healthcare database (Vårdanalysdatabasen) were followed for clinical outcomes during 2012 
(n=41 008) and 2017 (n=49 510).
Results—Pharmacy claims for oral anticoagulants increased from 51.6% to 73.8% (78.7% among those with CHA2DS2-
VASc ≥2). Non–vitamin K antagonist oral anticoagulant claims increased from 0.4% to 34.4%. Ischemic stroke incidence 
rates decreased from 2.01 per 100 person-years in 2012 to 1.17 in 2017 (incidence rate ratio, 0.58; 95% CI, 0.52–0.65). 
The largest increases in oral anticoagulants use and decreases in ischemic strokes were seen in patients aged ≥80 years 
who had the highest risk of stroke and bleeding. The incidence rates for major bleeding (2.59) remained unchanged 
(incidence rate ratio, 1.00; 95% CI, 0.92–1.09) even in those with a high bleeding risk. Poisson regression showed that 
10% of the absolute ischemic stroke reduction was associated with increased oral anticoagulants treatment, whereas 27% 
was related to a generally decreased risk for all stroke.
Conclusions—Increased oral anticoagulants use contributed to a marked reduction of ischemic strokes without increasing 
bleeding rates between 2012 and 2017. The largest stroke reduction was seen in elderly patients with the highest risks 
for stroke and bleeding. These findings strongly support the adoption of current guideline recommendations for stroke 
prevention in atrial fibrillation in both primary and secondary care.   (Stroke. 2018;49:2122-2128. DOI: 10.1161/
STROKEAHA.118.021990.)
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accumulating evidence has resulted in revisions of guideline 
recommendations16–18 and has been associated with substan-
tial increases in the utilization of NOACs in clinical practice 
all over the world,19 as well as in the Stockholm healthcare 
region.20 However, particularly in AF patients with a high 
stroke risk, in whom also bleeding concerns are common,8 
OACs have continued to be underused resulting in prevent-
able strokes.19,21
In addition to the early warfarin and ASA trials,4 2 relatively 
recent randomized studies have shown superiority of OAC com-
pared with ASA treatment in AF patients. However, these patients 
were relatively young and without serious comorbidities in 1 
study,5 and the majority of fragile patients were not considered 
eligible in the other.22 The American AF guidelines recommend 
either warfarin or a NOAC for patients with CHA2DS2-VASc ≥2 
with careful consideration to balance the benefits and risks of 
bleeding in each individual patient.18 The European AF guide-
lines prioritized NOACs over warfarin already in 2012 and have 
recently abandoned the recommendation to use the HAS-BLED 
scale (hypertension, abnormal renal and liver function, stroke, 
bleeding, labile INR, elderly, drugs or alcohol) to evaluate bleed-
ing risk in favor of reducing modifiable risk factors and treating 
also patients with a high bleeding risk with OACs.16 Both guide-
lines recommend strongly against prescribing ASA unnecessar-
ily. Thus, the question remains what risks and benefits can be 
seen with increasing OAC and decreasing ASA treatment in an 
entire nonselected AF population, which includes treatment of 
old and fragile patients in primary care.
The present study aims to investigate how antithrombotic 
treatment strategies and ischemic stroke and bleeding rates have 
changed after the adoption of recommendations for increased 
anticoagulant treatment and decreased utilization of ASA in AF. 
We compared these clinical outcomes in the entire AF popula-
tions of the Stockholm County during 2012 and 2017.
Methods
Data Source
We conducted a retrospective cohort study, using the 
Stockholm Healthcare Analyses Database (Vårdanalysdatabasen).7 
Vårdanalysdatabasen contains pseudonymized individual-level data 
for all inhabitants in the region (2.09 million in 2011 and 2.27 million 
in 2016), from both primary and secondary care, giving the unique 
possibility of complete healthcare data for follow-up of virtually all 
inhabitants.7 Demographic information, prescription claims, diagno-
ses, and healthcare consultations are linked using the personal iden-
tity number of each inhabitant.23 Data on secondary care (outpatient 
visits and hospitalizations) have been registered since 1993, primary 
care data since 2003, and pharmacy claims data since July 2010. 
Pharmacy data cover claims anywhere in the country and consist of 
amounts dispensed, expenditures and reimbursement, the age and sex 
of the patient, copayments, and prescriber category.24
The study was approved by the Regional Ethical Review Board in 
Stockholm (EPN 2015/579-31/2). Informed consent was not required 
in this registry study of anonymized data. Data are available on 
request from the authors.
Patient Selection
We created 2 cohorts for follow-up of clinical outcomes during 2012 
and 2017, respectively. For International Classification of Diseases 
Tenth Revision and Anatomical Therapeutic Chemical (ATC) codes 
(Table I in the online-only Data Supplement). All patients, alive 
and residents of the Stockholm County on December 31, 2011 and 
December 31, 2016, with a recorded diagnosis code for AF in the 
previous 5 years, were identified. Patients were excluded if they had a 
code for mechanical valves or mitral stenosis16 or if they moved into 
the region during the 5 years before the index date.
Treatment, Risk, and Outcome Definition
Treatments were assessed based on a claim of any OAC in 2011 and 
2016, respectively. Sensitivity analyses were conducted by defining 
treatment based on a claim in the last 6 months of 2011 and 2016. 
An additional analysis investigated patients switching and stopping 
treatment in the year of outcome.
The stroke risk was estimated with the CHA2DS2-VASc score.25 
Bleeding risk was assessed using a modified HAS-BLED score because 
international normalized ratio values were not available26 (hypertension 
+1, abnormal liver function +1, abnormal renal function +1, previous 
stroke +1, prior bleeding or anemia +1, age >65+1, alcohol misuse +1, 
medication use predisposing to bleeding +1). A HAS-BLED score of 3 
to 8 was considered high risk. Comorbidities were based on diagnoses 
recorded during the 5 years before the inclusion date.
The primary effectiveness outcome was ischemic stroke in 
acute somatic inpatient care as a primary or secondary diagnosis.14 
For safety, the primary outcome was a major bleed in acute somatic 
inpatient or outpatient care, including hemorrhagic stroke, intracra-
nial bleeding, bleeding requiring hospitalization, and gastrointestinal 
bleeding.14 Outcomes were assessed with censoring for death and 
migration. Rates of transient ischemic attack/ischemic and unspeci-
fied stroke and total mortality are also reported.14
In addition, exploratory comparisons of ischemic stroke and 
severe bleed in 2017 in patients with prevalent NOAC or warfarin 
treatment are presented. Patients who switched treatment during 2016 
were excluded.
Statistical Analysis
Basic descriptive statistics were used to describe the cohorts. With a 
Poisson regression, we calculated incidence rates (IR) and 95% CIs 
to compare outcomes between 2012 and 2017. Predefined stratified 
analyses were made for age, stroke, and bleeding risk groups.
To examine the influence of changed OAC-treatment strategies on 
ischemic stroke and major bleeds, we used stepwise adjustment for 
changes in demographic characteristics, baseline stroke and bleeding 
risks, and finally for OAC treatment
Results
Clinical Characteristics
A total of 41 008 and 49 510 patients with nonvalvular AF 
were included in the 2012 and 2017 cohorts, respectively 
(Figure I in the online-only Data Supplement). This corre-
sponds to 2.6% and 2.9% of the total adult populations of the 
Stockholm County. The demographics, clinical characteris-
tics, CHA2DS2-VASc, and HAS-BLED scores of the 2 cohorts 
were similar (Table 1).
Antithrombotic Treatment
In the 2012 cohort, 51.6% of the patients received treatment 
with any OAC, whereas there was a substantial increase to 
73.8% in the 2017 cohort (Table 2). A corresponding decrease 
could be seen in the number of patients with ASA mono-
therapy from 32.1% to 10.4%. In the 2017 cohort, 39.3%% 
had claimed only warfarin, and 34.4% claimed a NOAC. The 
proportion of patients receiving no antithrombotic treatment 
(ie, neither OAC nor ASA) was similar. In the 2017 cohort, a 
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in the year of outcome, and more patients switched from no 
OAC treatment to OAC treatment, compared with 2012 (Table 
II in the online-only Data Supplement).
The proportion of patients treated with an OAC increased 
in all age groups (Table 2). Notably, the largest increase was 
among the elderly (≥80 years of age), from 47.0% to 74.1%, 
as well as among potentially frail patients with simultaneously 
high CHA2DS2-VASc and HAS-BLED scores (Table 2).
Ischemic Stroke, Major Bleeding, 
and Total Mortality
Ischemic stroke IR decreased from 2.01 per 100 person-
years in 2012, to 1.17 in 2017 (IR ratio [IRR], 0.58; 95% 
Table 1. Baseline Table With Patient Characteristics in Each Cohort
 2012 (n=41 008) 2017 (n=49 510)
Male 22 818 (55.6%) 28 424 (57.4%)
Age, y, mean (SD) 74.6 (12.5) 75.0 (11.9)
  0–39 574 (1.4%) 509 (1.0%)
  40–64 7115 (17.4%) 7545 (15.2%)
  65–74 10 808 (26.4%) 14 344 (29.0%)
  75–79 6150 (15.0%) 8327 (16.8%)
  ≥80 16 361 (39.9%) 18 785 (37.9%)
CHA2DS2-VASc score, mean (SD) 3.62 (1.9) 3.66 (1.9)
  0 2368 (5.8%) 2560 (5.2%)
  1 3875 (9.5%) 4183 (8.5%)
  2–4 21 320 (52.0%) 26 594 (53.7%)
  5–9 13 445 (32.8%) 16 173 (32.7%)
HAS-BLED score, mean (SD) 2.37 (1.24) 2.28 (1.22)
  0 2543 (6.2%) 3289 (6.6%)
  1–2 20 508 (50.0%) 26 680 (53.9%)
  ≥3 17 957 (43.8%) 19 541 (39.5%)
Heart failure 13 408 (32.7%) 14 979 (30.3%)
Hypertension 25 990 (63.4%) 34 372 (69.4%)
TIA/stroke/systemic embolism 8007 (19.5%) 10 398 (21%)
Vascular disease 11 545 (28.2%) 11 862 (24.0%)
Diabetes mellitus 7891 (19.2%) 10 034 (20.3%)
Abnormal renal function 2866 (7.0%) 5524 (11.2%)
Abnormal liver function 555 (1.4%) 791 (1.6%)
Previous bleeding 2979 (7.3%) 4479 (9.1%)
Anemia 6497 (15.8%) 9897 (20.0%)
Alcohol misuse 1562 (3.8%) 1865 (3.8%)
Cancer 7783 (19.0%) 10 630 (21.5%)
Falls 3662 (8.9%) 6770 (13.7%)
Chronic obstructive pulmonary 
disease
3921 (9.6%) 5043 (10.2%)
Dementia 2589 (6.3%) 3462 (7.0%)
Obesity 2375 (5.8%) 3097 (6.3%)
Rate control drugs 29 839 (72.9%) 37 356 (75.5%)
Rhythm control drugs 3674 (8.9%) 3094 (6.3%)
Low-molecular weight heparins 2369 (5.8%) 2505 (5.1%)
Clopidogrel 1221 (3.0%) 1319 (2.7%)
Ticagrelor 9 (0.0%) 155 (0.3%)
Prasugrel 18 (0.0%) 11 (0.0%)
Antihypertensive drugs 37 067 (90.4%) 44 891 (90.7%)
Lipid-lowering drugs 15 201 (37.1%) 19 791 (40.0%)
Insulin 2743 (6.7%) 3496 (7.1%)
Oral antidiabetic drugs 3811 (9.3%) 5079 (10.3%)
Proton pump inhibitors 10 148 (24.8%) 13 258 (26.8)
CHA2DS2-VASc indicates congestive heart failure, hypertension, age ≥75 years, 
diabetes mellitus, stroke or TIA or thromboembolism, vascular disease, age 65–74 
years, sex category; HAS-BLED, hypertension, abnormal renal and liver function, 
stroke, bleeding, labile INR, elderly, drugs or alcohol; and TIA, transient ischemic attack.
Table 2. Antithrombotic Treatment Strategies in Each Cohort
Treatment 2012 (n=41 008) 2017 (n=49 510)
OAC, n (%) 21 152 (51.6) 36 515 (73.8)
  0–39 y 61 (10.6) 76 (14.9)
  40–64 y 2874 (40.4) 3759 (49.8)
  65–74 y 6682 (61.8) 11 701 (81.6)
  75–79 y 4002 (65.1) 7031 (84.4)





VASc 0 559 (23.6) 544 (21.3)
   HAS-BLED 0 412 (25.9) 475 (22.0)
   HAS-BLED 1–2 145 (18.9) 68 (17.7)





VASc 1 1599 (41.3) 2303 (55.1)
   HAS-BLED 0 274 (32.8) 339 (34.0)
   HAS-BLED 1–2 1296 (45.2) 1930 (62.9)





VASc 2–4 11 913 (55.9) 21 131 (79.5)
   HAS-BLED 0 83 (71.6) 96 (74.4)
   HAS-BLED 1–2 9376 (67.8) 16 338 (85.7)





VASc 5–9 7081 (52.7) 12 537 (77.5)
   HAS-BLED 0 0 0
   HAS-BLED 1–2 2494 (81.9) 3817 (91.9)
   HAS-BLED 3+ 4587 (44.1) 8720 (72.6)
  Warfarin 21 050 (51.3) 21 323 (43.1)
  NOAC 178 (0.4) 17 040 (34.4)
  Only warfarin 20 974 (51.2) 19 475 (39.3)
ASA, n (%) 16 491 (40.0) 7931 (16.0)
  No OAC 12 992 (31.7) 5112 (10.3)
No ASA or OAC, n (%) 6864 (16.7) 7883 (15.9)




VASc, congestive heart failure, 
hypertension, age ≥75 years, diabetes mellitus, stroke or TIA or thromboembolism, 
vascular disease, age 65 -74 years, sex category; HAS-BLED, hypertension, 
abnormal renal and liver function, stroke, bleeding, labile INR, elderly, drugs or 
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CI, 0.52–0.65; Table 3). The reduction of ischemic stroke 
was to a large extent driven by fewer strokes among elderly 
and high-risk patients (Figure 1A and 1B). The total mor-
tality (death as a noncompeting outcome) was significantly 
lower in the AF population in 2017 (IRR, 0.90; 95% CI, 
0.86–0.95).
Regarding safety outcomes, there was no significant 
change in major bleeding, with an IR of 2.59 in both cohorts, 
resulting in a crude IRR of 1.00; 95% CI, 0.92–1.09 (Table 3). 
The results were similar for all secondary bleeding end points, 
except hospitalized bleeding rates which had decreased in 
2017 (Table 3). Stratified analyses showed no differences 
between age-groups (Figure 1A) or CHA2DS2-VASc scores 
(Figure 1B).
The stroke reduction was most pronounced in patients 
with the largest relative increase of OAC treatment (ie, with 
HAS-BLED 3+ and increasing with the CHA2DS2-VASc 
score; Figure 2). The rates of major bleeds were high in these 
high-risk individuals but did not increase over the years.
Association Between Treatment and 
Ischemic Stroke and Major Bleeding
The crude IRR for ischemic stroke comparing the 2 cohorts 
was 0.58 (95% CI, 0.52–0.65; Table 4). Adding the CHA2DS2-
VASc score into the model resulted in an IRR of 0.63 (95% 
CI, 0.58–0.69). Adjusting for OAC treatment resulted in an 
IRR of 0.73 (95% CI, 0.66–0.80), indicating that an absolute 
10% reduction of ischemic strokes was associated with the 
increased OAC treatment.
The crude IRR for major bleeding comparing the 2 cohorts 
was 1.00 (95% CI, 0.92–1.09). Further adjustments did not 
result in any significant changes regarding major bleeding 
rates (Table 4).






(n=49 510) IRR (95% CI)
Effectiveness, (IR)
  Ischemic Stroke 2.01 1.18 0.58 (0.52–0.65)
  TIA/ischemic stroke/
unspecified stroke
2.70 1.72 0.64 (0.58–0.70)
Safety, (IR)
  Major bleeds 2.59 2.59 1.00 (0.92–1.09)
  Hospitalized bleeds 1.98 1.74 0.88 (0.79–0.97)
  Intracranial bleeds 0.78 0.85 1.09 (0.94–1.27)
  Hemorrhagic stroke 0.31 0.28 0.90 (0.70–1.15)
  Gastrointestinal 
bleeds
1.12 1.18 1.05 (0.93–1.20)
AF indicates atrial fibrillation; IR, incidence rate per 100 person-years; IRR, 
incidence rate ratio; and TIA, transient ischemic attack.
Figure 1. Incidence rates of ischemic stroke and major bleeding in 2012 and 2017, stratified by: (A) age group and (B) CHA2DS2-VASc score (congestive heart 
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Comparisons of prevalent treatment with NOAC or war-
farin revealed similar rates of ischemic stroke in 2017 after 
adjustment for the CHA2DS2-VASc score: NOAC versus war-
farin IRR, 0.89; 95% CI, 0.71–1.11. The rate of severe bleed-
ing after adjustment for the HAS-BLED score was lower with 
NOAC: IRR, 0.74; 95% CI, 0.65–0.85. The results were simi-
lar in patients with a high risk for both stroke and bleeding 
(Figure II in the online-only Data Supplement).
Discussion
In this population-based comparative cohort study, we com-
pared antithrombotic treatment patterns and clinical outcomes 
among patients with nonvalvular AF in an entire healthcare 
region with >2 million inhabitants. We found a considerable 
increase in the number of patients with AF. In the 2017 cohort, 
AF patients received OACs, in particular NOACs, much more 
frequently, whereas ASA treatment decreased correspond-
ingly compared with the 2012 cohort. NOAC use increased 
from 1% to 47% of OAC treated patients, and ASA mono-
therapy decreased from 31.7% to 10.3%. This is in line with 
international, as well as Swedish Guidelines.16–18 The larg-
est increases in OAC treatment were seen among potentially 
frail patients with high stroke risk and a simultaneously high 
bleeding risk. The changed treatment pattern was associated 
with a lower IR for ischemic stroke. Bleeding rates remained 
unchanged, and this was consistent throughout age groups 
and at different levels of baseline stroke and bleeding risks. 
All effectiveness outcomes occurred less frequently in 2017, 
whereas none of the bleeding outcomes increased.
Poisson regression models indicated that the increase in 
the proportion of patients treated with OACs played a signifi-
cant role in the reduction of stroke incidence. Adjusting for 
age, sex, and CHA2DS2-VASc scores influenced the IRRs lit-
tle, because of comparable characteristics of the populations in 
the 2 cohorts. Adjusting for OAC treatment provided an expla-
nation for 10% of the absolute reduction in ischemic stroke. 
Figure 2. Incidence rates of ischemic stroke 
and major bleeding in 2012 and 2017, stratified 
by CHA2DS2-VASc (congestive heart failure, 
hypertension, age ≥75 years, diabetes mellitus, 
stroke or TIA or thromboembolism, vascular 
disease, age 65–74 years, sex category) and 
HAS-BLED score (hypertension, abnormal renal 
and liver function, stroke, bleeding, labile INR, 
elderly, drugs or alcohol).
Table 4. IR and IRRs With 95% CIs for Ischemic Stroke and Major Bleeding
2012 2017 Calculated IRR (95% CI)
IR IR Crude












VASc or HAS-BLED 
Score and OAC Treatment
Ischemic stroke 2.01 1.18 0.58 (0.52–0.65) 0.64 (0.58–0.70) 0.63 (0.58–0.69) 0.73 (0.66–0.80)





VASc indicates congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA or thromboembolism, vascular disease, age 65-74 
years, sex category; HAS-BLED, hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, drugs or alcohol; IR, incidence rate per 100 person-
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This is consistent with results from randomized trials,4,5,22 
given the observed 22.2% absolute increase in OAC treated 
patients and a corresponding decrease of ASA treatment.
Comparison of NOAC or warfarin in 2017 indicates 
advantages with NOAC treatment, consistent with results 
from clinical trials.10–12 The risk of ischemic stroke was simi-
lar to the comparison in our previous observational study, 
which only included new initiations in previously OAC naïve 
AF patients,14 but bleeding rates were more favorable in the 
prevalent NOAC users of the present study. These results add 
to the knowledge that NOACs can be used in a beneficial and 
safe way in frail and elderly AF patients.
After adjustment for OAC treatment, an absolute 
decrease in ischemic stroke of ≈27% remained unexplained. 
An important factor could be the growing AF population 
as the increased awareness of AF with earlier detection of 
patients with a low AF burden might explain part of the 
observed decrease in the risk for ischemic stroke.27,28 Other 
explanations could be a better quality of anticoagulation 
with NOACs, but more switches or persistence to OAC 
treatment might also contribute (Table II in the online-only 
Data Supplement). In the total population of the Stockholm 
region, there was a 21% reduction of ischemic strokes 
(mainly non-AF related) between 2012 and 2017, with the 
largest reductions seen among the elderly (Figure III in the 
online-only Data Supplement). Potential explanations for 
this general improvement in stroke incidence could be an 
overall healthier population, with lower blood pressure lev-
els, healthier lifestyles, and better managed preventive drug 
treatment in the elderly.29,30
Both the American and European guidelines for stroke 
prevention in AF emphasize the value of increased OAC 
treatment,16,18 and the European guidelines have abandoned 
the use of bleeding risk scores to withhold OAC treatment.16 
Presently, the treatment goal recommended by the Swedish 
national board of health and welfare is to treat at least 80% 
of the AF patients with an OAC when a clear indication 
(eg, CHADS-VASc ≥2) is present.17 In the 2017 cohort, this 
goal was essentially reached, with 78.9% of patients with 
CHA2DS2-VASc scores 2 to 9 being treated. Yet, in selected 
patients, OACs may not be indicated, despite a high risk of 
stroke, and the optimal proportion of AF patients gaining a 
net benefit from OAC treatment remains unknown. However, 
our findings clearly demonstrate the clinical effectiveness and 
safety of achieving at least 80% on OAC treatment. In fact, the 
greatest stroke reduction associated with OAC use was seen in 
those patients with the highest stroke and bleeding risks, who 
in previous years often were left untreated or received less 
effective treatment with ASA.
Our study has some limitations. First, some diagno-
ses might be missing in the healthcare records. This might 
yield slight underestimation of stroke risks evaluated by the 
CHA2DS2-VASc score, as well as of both safety and effec-
tiveness outcomes. However, we have data also from primary 
care which increases the availability of comorbidities used 
for CHA2DS2-VASc scoring,7 and they were similar in the 2 
cohorts. Therefore, we do not think this has biased the results. 
Second, we did not include stopping or switching treatment 
strategy in our main analysis. To address this, we conducted 
additional analyses, which indicated an increased persistence 
and a larger portion of untreated patients switching to OAC 
treatment in later years (Table II in the online-only Data 
Supplement). Using a 6-month time interval to define OAC 
exposure yielded almost identical results. Because the main 
aim of the present study was not to compare the effectiveness 
of different antithrombotic treatments, we think the exposure 
definitions were sufficient.
One major strength of this study lies in the data used. 
The Vårdanalysdatabasen database contains International 
Classification of Diseases Tenth Revision codes for diagno-
ses and procedures from both primary and secondary care, as 
well as other data which provide comprehensive information 
about the patient. Previous work has investigated the value of 
primary care records for risk stratification,7 and 14% of the 
AF patients in the present cohorts could only be identified in 
primary care records. Second, we have contributed to the dif-
ficult but clinically important question of whether or not to 
treat frail and elderly patients with OACs. Further research 
is, however, needed to address the question which OAC treat-
ment is best for the frail and elderly and to better characterize 
high-risk populations, in whom withholding OAC treatment 
should be the preferred strategy. The large reduction of isch-
emic stroke within and outside of the AF population also mer-
its further exploration.
In conclusion, increasing OAC treatment because of the 
availability of NOACs in a complete, nonselected popula-
tion of patients with nonvalvular AF was associated with a 
marked reduction of ischemic stroke, although bleeding rates 
remained similar. The greatest clinical improvements were 
seen among elderly patients with elevated risks for both stroke 
and bleeding. These findings strongly support the adoption of 
current guideline recommendations for stroke prevention in 
AF in both primary and secondary care.
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